Reaction

Product Temperature Excursion Issue reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,685 reports · 72 co-occurring drugs

As of the last recalculation, Product Temperature Excursion Issue appears in 4,685 FAERS reports alongside 72 co-occurring drug terms. The strongest observed disproportionality signal is BRENTUXIMAB VEDOTIN (PRR 41.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Brentuximab Vedotin	94	41.6	41.9
Dronabinol	46	25.7	25.8
Ofatumumab	179	24.8	25.0
Inclisiran	33	18.4	18.5
Canakinumab	43	17.8	17.9
Alteplase	48	14.3	14.4
Guselkumab	97	12.3	12.3
Trametinib	55	10.2	10.2
Octreotide Acetate	66	9.7	9.7
Onabotulinumtoxina	144	8.5	8.5
Risankizumab-Rzaa	151	8.4	8.5
Botulinum Toxin Type A	22	7.9	7.9
Vedolizumab	149	7.9	7.9
Secukinumab	234	6.7	6.7
Ravulizumab	20	6.6	6.6
Ribociclib	46	6.5	6.5
Asfotase Alfa	14	6.2	6.2
Abatacept	170	5.6	5.6
Tocilizumab	131	5.2	5.2
Erenumab-Aooe	61	5.0	5.0
Infliximab-Dyyb	32	4.9	4.9
Dornase Alfa	21	4.8	4.8
Cyclobenzaprine Hydrochloride	9	4.5	4.5
Insulin Glulisine	10	4.4	4.4
Emtricitabine And Tenofovir Alafenamide	11	4.3	4.3
Icosapent Ethyl	8	4.2	4.2
Basiliximab	11	4.2	4.2
Epoetin Alfa	11	4.1	4.1
Lanreotide Acetate	7	4.0	4.0
Blinatumomab	8	3.4	3.4
Faricimab	6	3.3	3.3
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	13	3.2	3.2
Fremanezumab-Vfrm	8	3.1	3.1
Voclosporin	6	3.1	3.1
Omalizumab	58	3.0	3.1
Ocrelizumab	42	3.0	3.0
Romiplostim	10	3.0	3.0
Agalsidase Beta	6	2.9	2.9
Ado-Trastuzumab Emtansine	5	2.6	2.6
Darbepoetin Alfa	31	2.6	2.6
Insulin Glargine	139	2.5	2.6
Dabrafenib	12	2.5	2.5
Siponimod	5	2.5	2.5
Cannabidiol	13	2.5	2.5
Lifitegrast	9	2.5	2.5
Lisdexamfetamine Dimesylate	17	2.3	2.3
Pertuzumab	14	2.3	2.3
Polatuzumab Vedotin	5	2.3	2.3
Leuprolide Acetate	39	2.2	2.2
Ixazomib	14	2.2	2.2
Ozanimod Hydrochloride	4	2.1	2.1
Elexacaftor, Tezacaftor, And Ivacaftor	6	2.1	2.1
Abaloparatide	14	2.1	2.1
Ruxolitinib	34	2.1	2.1
Eculizumab	25	2.0	2.1
Evolocumab	70	1.9	1.9
Ustekinumab	42	1.8	1.8
Rimegepant Sulfate	5	1.8	1.8
Panitumumab	6	1.7	1.7
Paliperidone Palmitate	12	1.7	1.7
Iohexol	3	1.6	1.6
Aflibercept	11	1.6	1.6
Sarilumab	9	1.5	1.5
Relugolix	8	1.5	1.5
Emicizumab	4	1.4	1.4
Somatropin	23	1.4	1.4
Atezolizumab	11	1.3	1.3
Palivizumab	4	1.2	1.2
Buprenorphine	21	1.0	1.0
Bimekizumab	4	0.8	0.8
Dupilumab	83	0.8	0.8
Galcanezumab-Gnlm	4	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.